Mavorixafor
Mavorixafor is an oral CXCR4 antagonist used for the treatment of WHIM syndrome (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis), a rare genetic immunodeficiency disorder. By blocking the CXCR4 receptor, it helps restore normal white blood cell migration from the bone marrow to the bloodstream, improving immune function in affected patients.
An oral CXCR4 antagonist used to treat WHIM syndrome by improving white blood cell trafficking from the bone marrow.
Key facts at a glance
- ATC
- L03AX24
- RxNorm
- 2684021
- Generic
- Mavorixafor
- Class
- atc-l03
- Brands
- Xolremdi
- Availability
- rx
- Lactation
- unknown
- Routes
- oral
- Forms
- capsule
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
WHIM syndrome (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis) - a rare autosomal dominant immunodeficiency disorder characterized by severe neutropenia, hypogammaglobulinemia, recurrent infections, and warts. It is specifically indicated for patients 12 years and older.
Mavorixafor is an orally bioavailable CXCR4 receptor antagonist that blocks the binding of stromal-derived factor-1α (SDF-1α/CXCL12), the natural ligand for CXCR4. The SDF-1/CXCR4 axis plays a critical role in regulating trafficking and homing of leukocytes between the bloodstream and bone marrow. By antagonizing this receptor, mavorixafor promotes mobilization of neutrophils and other leukocytes from the bone marrow into circulation, thereby addressing the underlying pathophysiology of WHIM syndrome.
Should be taken once daily in the morning with food. Common side effects may include dizziness, rash, and bruising. Patients should have absolute neutrophil counts (ANC) monitored periodically during treatment. Not recommended for use in patients with severe renal or hepatic impairment. May interact with strong CYP3A4 inhibitors or inducers. Pregnancy category: Generally not recommended during pregnancy unless clearly needed.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy